

# 해외 바이오의약품 임상 현황 ('24년 2월 4주)

한국바이오의약품협회, 2024.02.27.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.  
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.  
- 출처: ClinicalTrials.gov  
- 모니터링 기간: 2024.02.19.~2024.02.25.  
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

## ○ 미국 10건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06275893</a>	IC14 (Atibudlimab) in Arrhythmogenic Cardiomyopathy	Biological: IC14	Implicit Bioscience	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06275893&amp;rank=1</a>
<a href="#">NCT06265220</a>	AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis	Drug: AB-101 Drug: Cyclophosphamide Drug: Fludarabine Drug: Rituximab	Artiva Biotherapeutics, Inc.	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06265220&amp;rank=1</a>
<a href="#">NCT06218602</a>	Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.	Drug: Fecal Microbiota Transplantation Procedure: Chemotherapy Procedure: CAR-T Therapy	M.D. Anderson Cancer Center	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06218602&amp;rank=1</a>
<a href="#">NCT06157151</a>	PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer	Biological: PRGN-2009 plus Pembrolizumab Drug: Pembrolizumab alone	Precigen, Inc National Cancer Institute (NCI)	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06157151&amp;rank=1</a>
<a href="#">NCT06088979</a>	A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 75 Years of Age With Thyroid Eye Disease	Drug: TOUR006 - 20 MG Other: Placebo Drug: TOUR006 - 50 MG	Tourmaline Bio, Inc.	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06088979&amp;rank=1</a>
<a href="#">NCT06267729</a>	Study of AZD0754 in Participants With Metastatic Prostate Cancer	Biological: AZD0754	AstraZeneca	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06267729&amp;rank=1</a>
<a href="#">NCT06265727</a>	A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701	Drug: CRB-701	Corbus Pharmaceuticals Inc. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06265727&amp;rank=1</a>
<a href="#">NCT06055608</a>	Advancing Transplantation Outcomes in Children	Drug: Sirolimus Biological: Belatacept Drug: Mycophenolate Mofetil Drug: Tacrolimus (Group1) Drug: Anti-Thymocyte Globulin (ATG) Drug: Tacrolimus (Group 2)	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06055608&amp;rank=1</a>
<a href="#">NCT05904080</a>	Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer	Procedure: Biospecimen Collection Drug: Cabozantinib S-malate Procedure: Computed Tomography Biological: Ipilimumab Procedure: Magnetic Resonance Imaging Biological: Nivolumab	National Cancer Institute (NCI)	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05904080&amp;rank=1</a>
<a href="#">NCT06260709</a>	A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis	Drug: NNC6019-0001	Novo Nordisk A/S	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06260709&amp;rank=1</a>

## ○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06265727</a>	A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701	Drug: CRB-701	Corbus Pharmaceuticals Inc. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06265727&amp;rank=1</a>

# 해외 바이오의약품 임상 현황 ('24년 2월 4주)

한국바이오의약품협회, 2024.02.27.

## ○ 프랑스 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06260709</a>	A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis	Drug: NNC6019-0001	Novo Nordisk A/S	Phase 2	<a href="https://clinicaltrials.gov/study/NCT06260709">https://clinicaltrials.gov/study/NCT06260709</a>

## ○ 독일 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06260709</a>	A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis	Drug: NNC6019-0001	Novo Nordisk A/S	Phase 2	<a href="https://clinicaltrials.gov/study/NCT06260709">https://clinicaltrials.gov/study/NCT06260709</a>

## ○ 중국 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06258811</a>	Neoadjuvant Immunochemotherapy for LAOSCC	Drug: albumin paclitaxel, cispatin, tislelizumab	Lai-ping Zhong Sun Yat-sen University Fudan University Central South University Fujian Medical University Huashan Hospital	Phase 3	<a href="https://clinicaltrials.gov/study/NCT06258811">https://clinicaltrials.gov/study/NCT06258811</a>
<a href="#">NCT06254521</a>	The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer	Drug: Tislelizumab combined with chemotherapy	First Affiliated Hospital of Guangxi Medical University	Phase 2	<a href="https://clinicaltrials.gov/study/NCT06254521">https://clinicaltrials.gov/study/NCT06254521</a>
<a href="#">NCT06251388</a>	A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab(AK104) for Newly Diagnosed Local Advanced Cervical Cancer	Drug: AK104	West China Second University Hospital Affiliated Hospital of North Sichuan Medical College The Affiliated Hospital Of Southwest Medical University	Phase 2	<a href="https://clinicaltrials.gov/study/NCT06251388">https://clinicaltrials.gov/study/NCT06251388</a>
<a href="#">NCT06222944</a>	Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA	Drug: Anlotinib Drug: TQB2450 Drug: Albumin-Bound Paclitaxel	Peking University Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2	<a href="https://clinicaltrials.gov/study/NCT06222944">https://clinicaltrials.gov/study/NCT06222944</a>
<a href="#">NCT06239727</a>	Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response	Drug: PD-1 blocking antibody Drug: Gemcitabine Drug: Cisplatin (80 mg/m2) Radiation: Reduced-dose Intensity-modulated radiotherapy Radiation: Conventional-dose Intensity-modulated radiotherapy Drug: Cisplatin (100 mg/m2) Drug: Capecitabine	Sun Yat-sen University Jiangsu Hengrui Pharmaceutical Co., Ltd.	Phase 3	<a href="https://clinicaltrials.gov/study/NCT06239727">https://clinicaltrials.gov/study/NCT06239727</a>